Biondo Investment Advisors LLC boosted its holdings in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 158.8% during the fourth quarter, HoldingsChannel reports. The firm owned 94,735 shares of the medical research company’s stock after purchasing an additional 58,135 shares during the period. EXACT Sciences makes up approximately 1.3% of Biondo Investment Advisors LLC’s holdings, making the stock its 23rd largest holding. Biondo Investment Advisors LLC’s holdings in EXACT Sciences were worth $4,977,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Lord Abbett & CO. LLC lifted its position in shares of EXACT Sciences by 59.1% in the second quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after acquiring an additional 875,527 shares in the last quarter. FMR LLC lifted its position in shares of EXACT Sciences by 32.7% in the second quarter. FMR LLC now owns 2,318,269 shares of the medical research company’s stock valued at $81,997,000 after acquiring an additional 571,796 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of EXACT Sciences by 82.9% in the fourth quarter. Victory Capital Management Inc. now owns 1,189,560 shares of the medical research company’s stock valued at $62,499,000 after acquiring an additional 539,160 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in shares of EXACT Sciences by 95.8% in the third quarter. Canada Pension Plan Investment Board now owns 930,000 shares of the medical research company’s stock valued at $43,822,000 after acquiring an additional 455,000 shares in the last quarter. Finally, Frontier Capital Management Co. LLC lifted its position in shares of EXACT Sciences by 163.0% in the third quarter. Frontier Capital Management Co. LLC now owns 916,713 shares of the medical research company’s stock valued at $43,196,000 after acquiring an additional 568,144 shares in the last quarter. Institutional investors own 82.32% of the company’s stock.

Shares of EXACT Sciences Co. (NASDAQ EXAS) opened at $45.90 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34. The stock has a market capitalization of $5,500.00, a price-to-earnings ratio of -39.91 and a beta of 0.58. EXACT Sciences Co. has a one year low of $18.30 and a one year high of $63.60.

Several research firms have recently weighed in on EXAS. BidaskClub upgraded EXACT Sciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Leerink Swann set a $67.00 target price on EXACT Sciences and gave the company a “buy” rating in a research report on Friday. Benchmark restated a “buy” rating and issued a $60.00 target price (up previously from $50.00) on shares of EXACT Sciences in a research report on Tuesday, October 31st. Goldman Sachs Group assumed coverage on EXACT Sciences in a research report on Monday, January 29th. They set a “neutral” rating and a $51.00 price objective on the stock. Finally, Bank of America lifted their price objective on EXACT Sciences from $56.00 to $58.00 and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. EXACT Sciences has an average rating of “Buy” and an average target price of $52.84.

In other EXACT Sciences news, insider Kevin T. Conroy sold 134,057 shares of the firm’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $59.50, for a total transaction of $7,976,391.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin T. Conroy sold 110,439 shares of the firm’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $50.49, for a total value of $5,576,065.11. Following the sale, the insider now directly owns 940,491 shares of the company’s stock, valued at approximately $47,485,390.59. The disclosure for this sale can be found here. In the last three months, insiders have sold 662,694 shares of company stock valued at $35,934,015. 4.00% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/exact-sciences-co-exas-holdings-boosted-by-biondo-investment-advisors-llc/1856554.html.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.